GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Pre-Tax Income

OncoCyte (STU:7OC0) Pre-Tax Income : €-22.87 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. OncoCyte's pretax income for the three months ended in Dec. 2023 was €-14.67 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €-22.87 Mil. OncoCyte's pretax margin was -5,092.01%.

During the past 11 years, OncoCyte's highest Pretax Margin was -1653.69%. The lowest was -2564.64%. And the median was -2174.11%.


OncoCyte Pre-Tax Income Historical Data

The historical data trend for OncoCyte's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Pre-Tax Income Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.18 -25.64 -46.79 -17.57 -22.79

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.34 5.57 -7.69 -6.08 -14.67

Competitive Comparison of OncoCyte's Pre-Tax Income

For the Diagnostics & Research subindustry, OncoCyte's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where OncoCyte's Pre-Tax Income falls into.



OncoCyte Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

OncoCyte's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-20.556+-2.188+-0.048+0+-3.5527136788005E-15
=-22.79

OncoCyte's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-4.635+-9.883+-0.147+0+0
=-14.67

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (STU:7OC0) Pre-Tax Income Explanation

OncoCyte's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-14.665/0.288
=-5,092.01%

During the past 11 years, OncoCyte's highest Pretax Margin was -1653.69%. The lowest was -2564.64%. And the median was -2174.11%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of OncoCyte's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (STU:7OC0) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines